Alan, who has over 20 years of global business and leadership experience, joined Abcam in August 2013 and has responsibility for the Company’s branding, product portfolio and online consumer offering.
Prior to joining Abcam, Alan spent 14 years with management consultant Bain & Company, most recently as head of the UK healthcare practice. Whilst at Bain he advised a wide range of global executives on consumer and marketing strategies to help achieve growth targets.
Mike Redmond, Abcam’s Chairman, commented: “I am delighted to welcome Alan to the Board. He has a huge amount of experience relevant to our growth strategies and he is already playing a major role in their planning and execution. We very much look forward to having his input at Board level, broadening his contribution to Abcam’s on-going development.”
About Abcam plc
Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level to improve the understanding of health and disease.
Abcam is committed to providing scientists with access to the correct reagents and tools for their research. The Company’s catalogue currently comprises more than 127,000 products and is continually evolving to meet customer needs. The range offered includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam products are supported with detailed, up-to-date and unbiased data on our website.
Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices and ships to over 100 countries. The Company was founded in 1998 and now employs over 700 people. Abcam is quoted on the AIM market of the London Stock Exchange (AIM: ABC).
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.